Provided by Tiger Trade Technology Pte. Ltd.

Amgen

405.49
-7.5900-1.84%
Volume:850.57K
Turnover:343.65M
Market Cap:218.35B
PE:25.19
High:411.84
Open:410.01
Low:400.06
Close:413.08
52wk High:447.03
52wk Low:288.00
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.51
T/O Rate:0.16%
Dividend:9.80
Dividend Rate:2.42%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:18.68
PE(LYR):28.50

Loading ...

Amgen Price Target Maintained with a $400.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 08

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 08

Beneath the Surface, the Next Market Leaders are Getting Ready to Break Out, Says Morgan Stanley

Dow Jones
·
Sep 08

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating

MT Newswires Live
·
Sep 08

Why Amgen Stock is Dropping After Swiss Rival's Trial Setback

Dow Jones
·
Sep 08

Amgen Falls After Novartis Trial Setback, BMO Downgrade

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Amgen downgraded to Market Perform from Outperform at BMO Capital

TIPRANKS
·
Sep 08

Amgen Shares Down 5.4% Premarket; Rival Novartis Cholesterol Drug Fails Late-Stage Study

THOMSON REUTERS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Movement Alert|Amgen Falls 5.08% in Pre-Market Trading, Novartis Lp(a) Heart Drug Phase III Failure Drags Down Peer Stocks

Market Focus
·
Sep 08

Movement Alert|Amgen Overnight Decline 5.27%, Dragged by Novartis Lp(a) Drug Trial Failure Casting Doubt on Cardiovascular Pipeline Thesis

Market Focus
·
Sep 08

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 07

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Reuters
·
Sep 07

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Stock News
·
Sep 07

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Dow Jones
·
Sep 06

Amgen EVP, CFO Thomas J.W. Dittrich Files Initial Beneficial Ownership Statement

Reuters
·
Sep 05

Movement Alert|Amgen Falls 5.08% in After-Hours Trading, Trading at $409.94

Market Focus
·
Sep 05

Amgen is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Sep 05